- Home
- WNC vs CRVS Comparison
WNC vs CRVS Comparison
Compare WNC & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WNC
- CRVS
- Stock Information
- Founded
- WNC 1985
- CRVS 2014
- Country
- WNC United States
- CRVS United States
- Employees
- WNC N/A
- CRVS N/A
- Industry
- WNC Construction/Ag Equipment/Trucks
- CRVS Biotechnology: Pharmaceutical Preparations
- Sector
- WNC Industrials
- CRVS Health Care
- Exchange
- WNC Nasdaq
- CRVS Nasdaq
- Market Cap
- WNC 457.3M
- CRVS 459.0M
- IPO Year
- WNC 1991
- CRVS 2016
- Fundamental
- Price
- WNC $11.41
- CRVS $5.86
- Analyst Decision
- WNC Hold
- CRVS Strong Buy
- Analyst Count
- WNC 1
- CRVS 4
- Target Price
- WNC $9.50
- CRVS $15.00
- AVG Volume (30 Days)
- WNC 481.9K
- CRVS 551.9K
- Earning Date
- WNC 10-23-2025
- CRVS 11-11-2025
- Dividend Yield
- WNC 2.84%
- CRVS N/A
- EPS Growth
- WNC N/A
- CRVS N/A
- EPS
- WNC N/A
- CRVS N/A
- Revenue
- WNC $1,720,560,000.00
- CRVS N/A
- Revenue This Year
- WNC N/A
- CRVS N/A
- Revenue Next Year
- WNC $18.05
- CRVS N/A
- P/E Ratio
- WNC N/A
- CRVS N/A
- Revenue Growth
- WNC N/A
- CRVS N/A
- 52 Week Low
- WNC $6.78
- CRVS $2.54
- 52 Week High
- WNC $20.63
- CRVS $10.00
- Technical
- Relative Strength Index (RSI)
- WNC 56.21
- CRVS 52.94
- Support Level
- WNC $11.08
- CRVS N/A
- Resistance Level
- WNC $11.50
- CRVS $6.09
- Average True Range (ATR)
- WNC 0.33
- CRVS 0.31
- MACD
- WNC -0.02
- CRVS -0.25
- Stochastic Oscillator
- WNC 56.00
- CRVS 93.02
About WNC Wabash National Corporation
Wabash National Corp operates as the innovation leader of connected solutions for the transportation, logistics, and distribution industries. The Company manages its business in two operating and reportable segments: Transportation Solutions and Parts & Services. It designs and manufactures products including dry freight and refrigerated trailers, platform trailers, tank trailers, dry and refrigerated truck bodies, structural composite panels and products, trailer aerodynamic solutions, and specialty food-grade processing equipment.
About CRVS Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).